Recent VC deals in the news
30th Aug 11
Two recent deals have been in the news. One concerns three VC funds - led by OneVentures, with co-investors Brandon Capital, the Medical Research Commercialisation Fund (MRCF) - injecting $15m into Australia's newest biotechnology start-up, Vaxxas and its needle-free vaccine delivery system, Nanopatch. The other concerns the divestment by Starfish Ventures of Energy Response, an energy management solutions company.
From The Australian Life Scientist:
Say “hello” to Australia’s newest biotechnology start-up, Vaxxas. With a fresh $15m boost of venture capital, Vaxxas will seek to develop and commercialise a needle-free vaccine delivery system, Nanopatch.
Nanopatch, which is the brainchild of Processor Mark Kendell of the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN), is a patch smaller than a postage stamp with thousands of small projections designed to deliver a vaccine to abundant immune cells in the skin.
From Starfish Ventures media release:
Starfish Ventures, Australia’s largest venture capital investor, is confident that the acquisition of Energy Response Pty Ltd, by EnerNOC, Inc (NASDAQ: ENOC), the world’s leading provider of demand response applications and services, has positive implications for Australians.
While the carbon debate rages, it is important to look at current renewable energy technology developments in Australia, and where the country can benefit from further investments in the sector, no matter how the debate is resolved.
Author: Yasser El-Ansary, Chief Executive, AVCAL
Author: Dr Noel Chambers, CEO, National Foundation for Medical Research and Innovation